Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:blackBoxWarning |
hyperglycemia
serious skin reactions |
| gptkbp:CASNumber |
2226850-87-6
|
| gptkbp:developer |
gptkb:Seagen
gptkb:Astellas_Pharma |
| gptkbp:firstBook |
yes
|
| gptkbp:form |
lyophilized powder for solution
|
| gptkbp:genericName |
gptkb:enfortumab_vedotin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Padcev
|
| gptkbp:indication |
bladder cancer
urothelial cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
gptkb:monoclonal_antibody
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.padcev.com/
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue alopecia peripheral neuropathy rash hyperglycemia decreased appetite |
| gptkbp:target |
gptkb:Nectin-4
|
| gptkbp:UNII |
6QX8J8QK8U
|
| gptkbp:bfsParent |
gptkb:Seagen
|
| gptkbp:bfsLayer |
5
|